SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-019351
Filing Date
2023-03-13
Accepted
2023-03-13 06:17:34
Documents
14
Period of Report
2023-03-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea175071-8k_nektartherap.htm   iXBRL 8-K 24983
2 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS ISSUES STATEMENT CONFIRMING THAT IT DO ea175071ex99-1_nektartherap.htm EX-99.1 2828
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2044
  Complete submission text file 0001213900-23-019351.txt   203148

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nktr-20230311.xsd EX-101.SCH 3221
5 XBRL LABEL FILE nktr-20230311_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE nktr-20230311_pre.xml EX-101.PRE 22355
8 EXTRACTED XBRL INSTANCE DOCUMENT ea175071-8k_nektartherap_htm.xml XML 3489
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

IRS No.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 23725617
SIC: 2834 Pharmaceutical Preparations